Literature DB >> 8546696

Characterization of an insulin from the three-toed amphiuma (Amphibia: Urodela) with an N-terminally extended A-chain and high receptor-binding affinity.

J M Conlon1, E S Cavanaugh, D C Mynarcik, J Whittaker.   

Abstract

Insulin was isolated from an extract of the pancreas of a urodele, the three-toed amphiuma (Amphiuma tridactylum), and its primary structure established as Ala-Arg-Gly-Ile-Val-Glu-Gln-Cys-Cys-His10-Asn-Thr-Cys- Ser-Leu-Asn-Gln-Leu-Glu-Asn20-Tyr-Cys-Asn for the A-chain and Ile-Thr-Asn-Gln-Tyr-Leu-Cys-Gly-Ser-His10-Leu-Val-Glu-Ala- Leu-Tyr-Leu-Val-Cys-Gly20-Asp-Arg-Gly-Phe-Phe-Tyr-Ser-Pro-Lys for the B-chain. The N-terminus of the A-chain is extended by two amino acids (Ala-Arg) relative to all other known insulins suggesting an anomalous pathway of post-translational processing in the region of the C-peptide/A-chain junction of proinsulin. In common with chicken and Xenopus insulins, which contain a HisA8, amphiuma insulin was more potent (approx. 5-fold) than porcine insulin in inhibiting the binding of [125I-TyrA14]insulin to the soluble human insulin receptor from transfected 293EBNA cells (an adenovirus-transformed human kidney cell line). This result is consistent with previous data showing that insulin analogues extended at GlyA1 by uncharged groups have reduced binding affinity whereas high affinity is preserved in analogues extended by basic amino acid residues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8546696      PMCID: PMC1216895          DOI: 10.1042/bj3130283

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain.

Authors:  J Markussen; P Hougaard; U Ribel; A R Sørensen; E Sørensen
Journal:  Protein Eng       Date:  1987-06

2.  The biological activity and the binding affinity of modified insulins determined on isolated rat fat cells.

Authors:  J Gliemann; S Gammeltoft
Journal:  Diabetologia       Date:  1974-04       Impact factor: 10.122

3.  Analogs of insulin. 1. Synthesis of destripeptide B 28-30 bovine insulin and destripeptide B 28-30 porcine (human) insulin.

Authors:  P G Katsoyannis; C Zalut; A Harris; R J Meyer
Journal:  Biochemistry       Date:  1971-10-12       Impact factor: 3.162

4.  Enhanced binding affinity of chicken insulin in rat liver membranes and human lymphocytes: relationship tothe kinetic properties of the hormone- receptor interaction.

Authors:  J Simon; P Freychet; G Rosselin; P DeMeyts
Journal:  Endocrinology       Date:  1977-01       Impact factor: 4.736

5.  Messenger RNA sequence and primary structure of preproinsulin in a primitive vertebrate, the Atlantic hagfish.

Authors:  S J Chan; S O Emdin; S C Kwok; J M Kramer; S Falkmer; D F Steiner
Journal:  J Biol Chem       Date:  1981-07-25       Impact factor: 5.157

6.  The evolution of genes: the chicken preproinsulin gene.

Authors:  F Perler; A Efstratiadis; P Lomedico; W Gilbert; R Kolodner; J Dodgson
Journal:  Cell       Date:  1980-06       Impact factor: 41.582

7.  The structure and evolution of the two nonallelic rat preproinsulin genes.

Authors:  P Lomedico; N Rosenthal; A Efstratidadis; W Gilbert; R Kolodner; R Tizard
Journal:  Cell       Date:  1979-10       Impact factor: 41.582

8.  Xenopus laevis contains two nonallelic preproinsulin genes. cDNA cloning and evolutionary perspective.

Authors:  A R Shuldiner; S Phillips; C T Roberts; D LeRoith; J Roth
Journal:  J Biol Chem       Date:  1989-06-05       Impact factor: 5.157

9.  Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion.

Authors:  C J Bailey; H Ahmed-Sorour
Journal:  Diabetologia       Date:  1980-11       Impact factor: 10.122

10.  Binding of insulin to bovine liver plasma membrane. Use of insulin analogues modified at the A1 residue.

Authors:  P Rösen; M Simon; H Reinauer
Journal:  Biochem J       Date:  1980-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.